Key Insights

Highlights

Success Rate

76% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

10.0%

8 terminated out of 80 trials

Success Rate

75.8%

-10.7% vs benchmark

Late-Stage Pipeline

9%

7 trials in Phase 3/4

Results Transparency

8%

2 of 25 completed with results

Key Signals

2 with results76% success

Data Visualizations

Phase Distribution

51Total
Not Applicable (25)
P 1 (6)
P 2 (13)
P 3 (7)

Trial Status

Completed25
Unknown19
Recruiting17
Terminated8
Not Yet Recruiting6
Active Not Recruiting4

Trial Success Rate

75.8%

Benchmark: 86.5%

Based on 25 completed trials

Clinical Trials (80)

Showing 20 of 20 trials
NCT06440174RecruitingPrimary

Understanding the Variation of Modern Endoscopic Ultrasound Use in Patients With Oesophageal Cancer (VALUE)

NCT05357846Phase 3Recruiting

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

NCT06447064Recruiting

Cancer Loyalty Card Study 2 (CLOCS-2)

NCT05143970Phase 1Recruiting

A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors

NCT05489250Terminated

The PLATON Network

NCT07260734Not Yet Recruiting

AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)

NCT05642819Recruiting

REVOLUTION Surgery (REVOLUTION Surgery)

NCT07233850Phase 2Not Yet Recruiting

A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers

NCT07159711Not Yet RecruitingPrimary

Evaluation of Seismocardiography(SCG) for Assessing Fitness and Predicting Outcomes in Oesophageal Cancer Surgery

NCT05057013Phase 1Active Not Recruiting

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

NCT06364553Not ApplicableRecruitingPrimary

Esophageal Self-expandable Metal Stent for Malignant Strictures: a Safety and Efficacy Study

NCT06277921Completed

Morbidity and Mortality After Esophageal and Esophagogastric Junction Cancer Surgery

NCT06906887Phase 2Recruiting

PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer

NCT06965205Not ApplicableNot Yet RecruitingPrimary

Use of Different Enteral Feeds to Impact on Chyle Leaks in Oesophagectomy

NCT03212469Phase 1Completed

A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer

NCT06169163Recruiting

Volatile Organic Compounds as Breath Biomarkers in Squamous Oesophageal Neoplasms

NCT03653052Phase 2Active Not RecruitingPrimary

Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab

NCT05804331Recruiting

The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study

NCT03978377RecruitingPrimary

Cardiopulmonary Toxicity of Thoracic Radiotherapy

NCT04484636Not ApplicableCompleted

PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)

Scroll to load more

Research Network

Activity Timeline